Form 8-K - Current report:
SEC Accession No. 0001193125-22-015468
Filing Date
2022-01-24
Accepted
2022-01-24 07:31:01
Documents
14
Period of Report
2022-01-24
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d298787d8k.htm   iXBRL 8-K 24965
2 EX-99.1 d298787dex991.htm EX-99.1 11608
6 GRAPHIC g298787g0124024451004.jpg GRAPHIC 4093
  Complete submission text file 0001193125-22-015468.txt   168649

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tcrx-20220124.xsd EX-101.SCH 2852
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tcrx-20220124_lab.xml EX-101.LAB 17980
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tcrx-20220124_pre.xml EX-101.PRE 11256
8 EXTRACTED XBRL INSTANCE DOCUMENT d298787d8k_htm.xml XML 3344
Mailing Address 830 WINTER STREET WALTHAM MA 02451
Business Address 830 WINTER STREET WALTHAM MA 02451 857-399-9500
TScan Therapeutics, Inc. (Filer) CIK: 0001783328 (see all company filings)

EIN.: 825282075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40603 | Film No.: 22547550
SIC: 2836 Biological Products, (No Diagnostic Substances)